Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Ipamorelin vs GHRP-2 and GHRP-6 GHRP Family Side-by-Side Feature Receptor Ipamorelin GHS-R1a GHRP-2 GHS-R1a GHRP-6 GHS-R1a Feature Half-life Ipamorelin ~2 hours GHRP-2 ~25-30 minutes GHRP-6 ~20-30 minutes Feature Dosing Ipamorelin 1-3x daily (SubQ) GHRP-2 2-3x daily (SubQ) GHRP-6 2-3x daily (SubQ) Feature Standard dose Ipamorelin 100-300 mcg GHRP-2 100-300 mcg GHRP-6 100-300 mcg Feature Cortisol effect Ipamorelin None at standard doses GHRP-2 Yes GHRP-6 Yes Feature Prolactin effect Ipamorelin None GHRP-2 Moderate GHRP-6 Minimal Feature Appetite effect Ipamorelin Mild GHRP-2 Moderate GHRP-6 Strong Feature FDA status Ipamorelin Not approved GHRP-2 Not approved GHRP-6 Not approved All three target the same receptor
Patients who already qualify for GLP-1 therapy and would like additional support Individuals with suboptimal B12 levels or risk of deficiency Those who prefer combining metabolic and micronutrient therapy Patients fully committed to close medical oversight and follow-up However, its not recommended if you have contraindications to GLP-1 agents, are pregnant, breastfeeding, have uncontrolled GI disease, or cannot adhere to monitoring and follow-up
Caveolin-1 promotes cancer progression via inhibiting ferroptosis in head and neck squamous cell carcinoma
Treatment of Overdose In instances of antiarrhythmic drug overdose, medical professionals must ensure the patient has a clear airway, adequate breathing, and support for circulation [4] [87]
Informed consent was obtained for the publication of this case report
Pricing and Warranty Notice : All pricing is brand-stated as of June 2026 and subject to change without notice
